The February 2010 retraction of the original Wakefield paper in the Lancet was, of course, a huge deal. If there were a Canon of Scientific Retractions, it would be in it. It happened before we launched Retraction Watch, however, so we haven’t commented much on it.
We plan on writing about major retractions in history, but the frequency of fascinating timely ones hasn’t abated enough yet to let us do that. (One exception: Our Best of Retractions series.) And in any case, there have been a lot of pixels spilled on this one already, so we’re not sure we have much to add. That’s the nice thing about the web: It leaves us free to curate as well as create.
A leading Japanese virologist has received a 10-year publishing ban from the American Society of Microbiology after many of his published articles were found to have evidence of data manipulation.
In its January 2011 issue, Infection and Immunity, an ASM title, is retracting five articles by the researcher, Naoki Mori, of the University of Ryukyus in Okinawa. The articles, published between 2000 and 2009, involve work on Helicobacter pylori which Nori conducted with co-authors from the United States and elsewhere. Some of the studies listed co-authors from drug companies, including Merck and Boehringer Ingelheim, although it’s not clear whether the companies helped support any of the research.
In fact, their initial public offering (IPO) happened today, and you can follow the price of their stock — listed on the Stockholm Stock Exchange as WNT — here. But what we learned when we looked into the IPO was that it was originally scheduled for late November, and was delayed because of the retraction.
Tommy Andersson, one of the researchers on the now-retracted paper and Wnt Research’s chief scientific officer, told Retraction Watch that the company had initially planned on going public on November 26. They had written a memorandum describing the company’s work to date, and its plans, and the public was given a chance to invest before shares hit the Stockholm exchange. That memorandum included a mention of the PNAS paper, as follows (translated from Swedish): Continue reading Wnt Research: How a retraction delayed an IPO, shrunk investment — but should build public trust
According to an article in the Weinheimer Nachrichten, that incident occurred when Boldt was at the University Hospital Giessen. Officials there told us there was an investigation into the matter but declined to comment further.
One of the journals in which Hamman published, the American Journal of Medical Quality, will “amend the paper to correct” Hamman’s credentials — or lack thereof, a journal staffer told us today. The journal hasn’t dealt with this sort of thing before, so is checking with the publisher before making the change. They “plan to get it done as quickly as they can do it.”
photo of Frank Abagnale, Jr., whose story is the basis of Catch Me If You Can, by marcus_jb1973 via flickr http://www.flickr.com/photos/marcusjb/
It’s a mind-boggling story: A United Airlines pilot claims to be a cardiologist and was eagerly sought after for medical conferences at which he taught doctors teamwork. He shared millions in grants, according to the Associated Press. But as the AP reports, William Hamman wasn’t a cardiologist at all, having never even finished medical school.
Hamman’s career seems to be collapsing, now that he resigned from his post as a researcher and educator at Royal Oak, Michigan’s William Beaumont Hospital once the hospital found out he had misled them. (Just last year, Beaumont touted a $150,000 grant Hamman nabbed with a colleague, Marc Abramson at Improbable Research notes.) United has also grounded him.
The storyline is reminiscent of 2002’s Catch Me If You Can, in which Frank Abagnale Jr. (played by Leonardo DiCaprio) forges millions of dollars’ worth of checks around the world, in the process impersonating a Pan Am pilot and a doctor. In Hamman’s case, there are apparently no questions over whether his pilot credentials are legit, according to the AP.
We have an update on the case of Olav and Axel Gressner, a father-son (or, in this case, son-father) pair of German liver researchers caught up in a fraud investigation. The inquiry focused on Olav, who left the University of Aachen under a cloud of suspicion. A 2008 research letter on which he was a co-author (his father was senior author) was retracted earlier this year by the Journal of Hepatology.
It’s fair to say that we haven’t heard the last of Anil Potti, the Duke cancer researcher who resigned last month following revelations that he had faked some of his results. Duke is still investigating the situation, and has also asked the Institute of Medicine to conduct its own study into the case and its ramifications.
The authors of a 2009 study in the Proceedings of the National Academy of Sciences (PNAS) have retracted the paper, which found a particular molecule could make breast tumors respond to a drug to which they’re not normally susceptible.
The paper — which has been cited five times, according to Thomson Scientific’s Web of Knowledge — was the subject of a fair amount of press coverage, although the molecule is not yet in clinical trials. In a Reuters story, lead author Caroline Ford said of the alleged tamoxifen-sensitizing compound, Foxy-5:
“It flips the switch basically,” Ford said in a telephone interview. “It makes breast cancer cells respond to tamoxifen in women who cannot be treated with the drug,” she added. “If you don’t have that molecule you can’t get tamoxifen because there is no target.”
At least one of the dominoes may be falling from a scandal at Research Center Borstel.
